In summary, mosunetuzumab monotherapy is a well-tolerated, off-the-shelf agent that can be delivered in an outpatient setting, with activity in patients with R/R DLBCL, including those with trFL. Its administration as a fixed-duration regimen minimizes the potential for long-term or cumulative...
In summary, this study indicates promising activity of convenient subcutaneous mosunetuzumab for frontline follicular lymphoma patients requiring treatment. Larger studies with longer follow-up are needed to confirm safety and durable efficacy. But given the high response rates, manageable toxicity, and ...
Risk Summary Based on the mechanism of action, LUNSUMIO may cause fetal harm when administered to a pregnant woman [seeCLINICAL PHARMACOLOGY]. There are no available data on the use of LUNSUMIO in pregnant women to evaluate for a drug-associated risk. No animal reproductive or developmental tox...
The ATE estimation requires availability of IPD for both treatments, which in real-world applications usually come from clinical trial or registry/claims data. For this study, trial data on OS and progression-free survival (PFS) were available and were preferred as they typically represent a highe...